Chemotherapy Induced Neutropenia Market Size to Exhibit Considerable Growth at a CAGR of 1 76% in the 7MM for the Study Period (2018-2030), Estimates DelveInsight
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Chemotherapy Induced Neutropenia Market Size to Exhibit Considerable Growth at a CAGR of 1 76% in the 7MM for the Study Period (2018-2030), Estimates DelveInsight
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Chemotherapy Induced Neutropenia Market Size to Exhibit Considerable Growth at a CAGR of 1 76% in the 7MM for the Study Period (2018-2030), Estimates DelveInsight
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Tetra Bio-Pharma: Health Canada Accepts New Drug Submission for REDUVO as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting
The Company approaches a significant milestone advancing from a pre-revenue biotech to in revenue
OTTAWA, ON / ACCESSWIRE / June 2, 2021 /
Tetra Bio-Pharma
Inc. ( Tetra or the Company ) (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development announced today that Health Canada has accepted its New Drug Submission (NDS) for REDUVO and has formally entered the final review phase in the drug review process. If successful, REDUVO will be issued a Notice of Compliance (NOC) as well as a Drug Identification Number (DIN) which permits Tetra to market the drug in Canada and indicates the drug s official approval in Canada.